Johns Hopkins Center for Alternatives to Animal Testing (CAAT)

What Johns Hopkins Center for Alternatives to Animal Testing (CAAT) does

The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) is an academic research center established in 1981 within the Johns Hopkins Bloomberg School of Public Health. The center develops biotechnologies, educational initiatives, and multi-stakeholder events designed to advance the shift away from animal models in toxicology, with the stated objective of increasing specificity, human relevance, and the humane treatment of animals in clinical and research settings. CAAT serves researchers, academic institutions, policymakers, and industry stakeholders engaged in toxicology and biomedical research, operating as a horizontal-platform organization rather than a vertical product vendor.

CAAT's core programmatic areas are: GreenTox and ToxAIcology (green toxicology and artificial intelligence applications in toxicology), Micro-physiological Systems (organ-on-chip and related micro-physiological technologies for human-relevant testing), Exposomics (the study of environmental exposures and their health effects using non-animal methods), Humane Education and the 3Rs (Replacement, Reduction, and Refinement principles in animal research), the Evidence-Based Toxicology Collaborative, and Organoid Intelligence. These are research focus areas and collaborative initiatives, not commercial products. CAAT maintains strategic partnerships with the Lena Smirnova Lab (micro-physiological systems), the Global Exposome Forum (exposomics), the Evidence-Based Toxicology Collaborative, and the Organoid Intelligence Consortium.

CAAT is a non-commercial entity and does not sell products, license software, or charge user fees. Its operations are funded through institutional support from Johns Hopkins University, external grants and awards programs that channel funding outward to researchers, and donor contributions (a 'Make a Gift' facility is published on the CAAT website). The center exercises global reach through its grant programs and collaborative networks rather than commercial distribution. The source data discloses no headcount, no revenue figures, no funding round history, and no commercial pricing, and the center is classified as a private academic research institution domiciled in Maryland, USA.

Name

Johns Hopkins Center for Alternatives to Animal Testing (CAAT)

Legal name

Johns Hopkins Center for Alternatives to Animal Testing

Website

https://caat.jhsph.edu

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

11–50 employees

Short description

Johns Hopkins Center for Alternatives to Animal Testing (CAAT), founded in 1981, is an academic research center that advances biotechnologies replacing animal models in toxicology, serving researchers, institutions, and policymakers through grants, education, and collaborative programs.

Ownership category

akta.pro rank

Product category

Academic Toxicology Research Services

NAICS

Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH), Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)

Keywords

• Alternatives to animal testing
• Human-relevant toxicology research
• 3Rs humane research principles
• Micro-physiological systems research
• Evidence-based toxicology collaboration

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels3 records

Core offering

CAAT is an academic research center that funds, coordinates, and disseminates research on alternatives to animal testing in toxicology. It operates themed research programs (GreenTox, ToxAIcology, Micro-physiological Systems, Exposomics, Organoid Intelligence, Evidence-Based Toxicology, and 3Rs Humane Education), administers grants and awards, and convenes researchers, policymakers, and industry stakeholders through educational initiatives and events.

Product overview

CAAT is an academic research center at Johns Hopkins University, not a commercial product company. It does not offer products or services in the traditional software/SaaS sense. Instead, CAAT operates as a research and education organization focused on developing alternatives to animal testing in toxicology. Its activities center on grant programs, educational initiatives, and multi-stakeholder events that promote the development and adoption of human-relevant testing methods. CAAT's core programs include GreenTox and ToxAIcology, Micro-physiological Systems, Exposomics, Humane Education and the 3Rs, the Evidence-Based Toxicology Collaborative, and Organoid Intelligence — these are research focus areas and collaborative initiatives, not commercial products.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Lena Smirnova LabcoreTechnology or IntegrationCollaborative research partnership focused on Micro-physiological Systems research, connecting CAAT with academic expertise in organ-on-chip and related technologies.
• Global Exposome ForumcoreStrategic or Co-development PartnerPartnership for Exposomics research initiatives, advancing the study of environmental exposures and their effects on human health using non-animal testing approaches.
• Evidence-Based Toxicology Collaborative (EBT)coreStrategic or Co-development PartnerCollaborative initiative advancing evidence-based approaches in toxicology, promoting rigorous scientific standards for alternative testing methods.
• Organoid Intelligence ConsortiumcoreStrategic or Co-development PartnerPartnership focused on Organoid Intelligence research combining organoid technology with computational approaches for biomedical applications.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Emerging players

• MIMETAS: Dutch organ-on-chip company developing microfluidic disease and toxicology models — directly comparable to CAAT's micro-physiological systems work as a commercial translator of academic alternative-methods research.
• Emulate, Inc. Commercial organ-on-chip company commercializing micro-physiological systems for drug development — operates in CAAT's Micro-physiological Systems research domain and represents the commercial counterpart advancing similar technology toward pharma adoption.
• InSphero AG: Commercial organoid and 3D microtissue technology company serving pharmaceutical and toxicology clients — adjacent to CAAT's micro-physiological and organoid research programs with direct overlap in in vitro human-relevant toxicology methods.
• Hesperos, Inc. Commercial human-on-a-chip company developing multi-organ systems for toxicology and disease modeling — directly comparable to CAAT's micro-physiological systems research, representing commercial translation of academic NAMs.

Direct peers

• National Centre for the 3Rs (NC3Rs): UK-based scientific organization advancing the Replacement, Reduction, and Refinement (3Rs) of animal use in research — directly comparable mission to CAAT, operating as a funding and convening body for non-animal alternatives.
• PETA International Science Consortium Ltd. Non-profit science consortium funding development and regulatory uptake of non-animal test methods — directly comparable mission to CAAT with overlapping focus on toxicology method development and stakeholder convening.
• European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM): EU Joint Research Centre unit responsible for development, validation, and regulatory acceptance of alternative methods — directly comparable in mission to advance non-animal toxicology and serve as an authoritative validation hub.
• Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): U.S. federal interagency committee promoting toxicological test method validation and regulatory acceptance of alternatives — closely aligned with CAAT's role in advancing evidence-based, non-animal toxicology methods.

Broad incumbents

• The Humane Society of the United States — Animal Research Issues: Major animal-welfare organization that funds and advocates for alternatives to animal testing — operates a broader animal-protection portfolio but overlaps with CAAT on advancing non-animal research methods and humane education (3Rs).
• Physicians Committee for Responsible Medicine: Non-profit advocacy and research organization promoting alternatives to animal use in medical research and education — broader portfolio than CAAT but overlapping interest in advancing human-relevant, non-animal research methods.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/jhu-caat

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johns Hopkins Center for Alternatives to Animal Testing (CAAT)